BMS, Gilead Ink Deal for Atripla in Europe

Bristol-Myers Squibb (BMS) and Gilead Sciences have signed an agreement to commercialize Atripla, a treatment for HIV, in Europe.

If approved by the European Commission (EC), Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) would be the first once-daily tablet regimen for HIV-1 infection in the European Union (EU).

BMS and Gilead share responsibility for commercializing the drug throughout the EU and other European countries, Gilead said.

The companies expect the EC to issue its decision by the end of the year.